Med Sci (Paris)
Volume 37, Number 6-7, Juin-Juillet 2021
Nos jeunes pousses ont du talent !
Page(s) 677 - 680
Section Partenariat médecine/sciences - Écoles doctorales - Masters
Published online 28 June 2021
  1. Jiang M, Chen P, Wang L, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol 2020; 13 : 81. [CrossRef] [PubMed] [Google Scholar]
  2. Motwani M, Pesiridis S, Fitzgerald KA DNA sensing by the cGAS–STING pathway in health and disease. Nat Rev Gene 2019 ; 20 : 657–674. [Google Scholar]
  3. Mackenzie K.J., Carroll P, Martin CA, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 2017 ; 548 : 461–465. [CrossRef] [PubMed] [Google Scholar]
  4. Harding S.M., Benci J.L., Irianto J, et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 2017 ; 548 : 466–470. [CrossRef] [PubMed] [Google Scholar]
  5. Dou Z, Ghosh K, Vizioli MG, et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 2017 ; 550 : 402–406. [CrossRef] [PubMed] [Google Scholar]
  6. Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med 2011 ; 208 : 2005–2016. [CrossRef] [PubMed] [Google Scholar]
  7. Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011 ; 208 : 1989–2003. [CrossRef] [PubMed] [Google Scholar]
  8. Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014 ; 41 : 843–852. [CrossRef] [PubMed] [Google Scholar]
  9. Marcus A, Mao AJ, Lensink-Vasan M, et al. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 2018 ; 49 : 754–63 e4. [Google Scholar]
  10. Kwon J, and Bakhoum SF. The Cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov 2020; 10 : 26–39. [CrossRef] [PubMed] [Google Scholar]
  11. Konno H, Yamauchi S, Berglund A, et al. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 2018 ; 37 : 2037–2051. [CrossRef] [PubMed] [Google Scholar]
  12. Wu S, Zhang Q, Zhang F, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol 2019 ; 21 : 1027–1040. [CrossRef] [PubMed] [Google Scholar]
  13. Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015 ; 11 : 1018–1030. [CrossRef] [PubMed] [Google Scholar]
  14. Demaria O, Gassart AD, Coso S, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc Natl Acad Sci USA 2015 ; 112 : 15408–15413. [Google Scholar]
  15. Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014 ; 41 : 830–842. [CrossRef] [PubMed] [Google Scholar]
  16. Harrington KJ, Brody J, Ingham M, et al. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. Ann Oncol 2018; 29 : viii712. [Google Scholar]
  17. Meric-Bernstam F, Sandhu SK, Hamid O, et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. JCO 2019 ; 37 : 2507. [Google Scholar]
  18. Chin EN, Yu C, Vartabedian, VF, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 2020; 369 : 993–9. [CrossRef] [PubMed] [Google Scholar]
  19. Pan BS, Perera SA, Piesvaux JA, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 2020; 369 : eaba6098. doi: 10.1126/science.aba6098. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.